Physician
University of Maryland Medical Center, LLC
University of Maryland Medical Center, LLC was paid $9.24M by Medicaid between Jan 2018 and Dec 2024, across 185 billing codes. Its largest line is 99285, emergency room visit (most serious) — 22% of everything it billed.
33Billing provider infoUNIVERSITY OF MARYLAND MEDICAL CENTER, LLC
BALTIMORE, MD 21201
BALTIMORE, MD 21201
33aNPI1174660120assigned 01/31/2007
33bProvider typeTransplant Surgery Physician
28Total paid$9.24M
24GClaims325,620
24DCodes billed185
24AFirst – last monthJan 2018 – Dec 2024
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official SPRINKEL, GEORGE controls 15+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 61,067 | $1.56M | |
| 2019 | 56,115 | $1.57M | |
| 2020 | 37,894 | $1.34M | |
| 2021 | 48,922 | $1.48M | |
| 2022 | 49,875 | $1.33M | |
| 2023 | 44,623 | $1.22M | |
| 2024incomplete | 27,124 | $745K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 22% | 7,701 | 6,570 | $1.99M |
| 41899 | Unlisted procedure, dentoalveolar structures | 21% | 745 | 661 | $1.97M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 12% | 44,458 | 36,336 | $1.13M |
| G0378 | Hospital observation service, per hour | 8.1% | 2,106 | 1,857 | $750K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 8.1% | 3,712 | 3,199 | $744K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 5.3% | 3,405 | 2,731 | $490K |
| 90832 | Psychotherapy session, about 30 minutesPsychotherapy, 30 minutes with patient | 4.0% | 12,524 | 8,173 | $372K |
| J9271 | Injection, pembrolizumab, 1 mg | 3.0% | 124 | 86 | $278K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 2.7% | 5,754 | 3,548 | $250K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.2% | 2,705 | 1,714 | $206K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.8% | 2,211 | 1,588 | $170K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.2% | 2,406 | 914 | $109K |
173 more codes
| 36591 | 1.1% | 3,513 | $102K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 357 | $75K |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 1,926 | $73K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 3,852 | $37K |
| 36592 | <1% | 1,122 | $35K | |
| 90837 | Psychotherapy session, about an hour | <1% | 785 | $34K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,810 | $32K |
| 80053 | Comprehensive metabolic panel | <1% | 25,605 | $27K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 3,005 | $26K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 380 | $22K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 983 | $21K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,809 | $19K |
| 82784 | <1% | 722 | $19K | |
| 77066 | Tomosynthesis, mammo | <1% | 75 | $18K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 2,145 | $17K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 785 | $16K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 755 | $12K |
| 31575 | <1% | 101 | $11K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 3,171 | $11K |
| 96367 | <1% | 1,095 | $11K | |
| 96415 | <1% | 351 | $10K | |
| 88341 | <1% | 210 | $9K | |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 3,100 | $8K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 4,776 | $8K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 711 | $8K |
| 84484 | <1% | 3,492 | $7K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 129 | $7K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 23,927 | $7K |
| 86900 | <1% | 4,608 | $6K | |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 15 | $6K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,232 | $5K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 84 | $5K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 1,832 | $4K |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 109 | $4K |
| 84100 | <1% | 11,390 | $4K | |
| 85027 | <1% | 5,831 | $3K | |
| 90694 | <1% | 90 | $3K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 431 | $3K |
| 71045 | Radiologic examination, chest; single view | <1% | 3,142 | $3K |
| 83605 | <1% | 1,364 | $3K | |
| 88342 | <1% | 442 | $3K | |
| 85610 | <1% | 6,617 | $2K | |
| 86850 | <1% | 4,616 | $2K | |
| 86901 | <1% | 4,522 | $2K | |
| 86832 | <1% | 40 | $2K | |
| 93970 | <1% | 15 | $2K | |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 1,834 | $2K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 35 | $2K |
| 74174 | <1% | 37 | $2K | |
| 85730 | <1% | 3,781 | $2K | |
| 76942 | <1% | 38 | $2K | |
| 94010 | <1% | 25 | $2K | |
| Q5106 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | <1% | 28 | $2K |
| 83735 | <1% | 15,152 | $1K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 342 | $1K |
| 92557 | <1% | 14 | $1K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 11,319 | $1K |
| 81001 | <1% | 5,426 | $1K | |
| 82728 | <1% | 2,013 | $1K | |
| 93971 | <1% | 29 | $975.37 | |
| J2704 | Injection, propofol, 10 mg | <1% | 2,955 | $922.37 |
| 76642 | <1% | 114 | $917.65 | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 75 | $913.50 |
| 85384 | <1% | 537 | $842.43 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 112 | $685.31 |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,118 | $654.64 |
| 96401 | <1% | 44 | $642.29 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 911 | $634.56 |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 193 | $623.58 |
| 85007 | <1% | 405 | $570.84 | |
| 83615 | <1% | 5,491 | $560.54 | |
| 86140 | <1% | 1,672 | $549.51 | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 190 | $484.69 |
| 83690 | <1% | 1,815 | $396.60 | |
| 84703 | <1% | 319 | $389.23 | |
| 73610 | <1% | 56 | $366.97 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 3,570 | $360.27 |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 209 | $316.98 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 414 | $307.56 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 394 | $305.22 |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 601 | $300.52 |
| 93017 | <1% | 255 | $298.45 | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 37 | $289.90 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 991 | $283.02 |
| 82150 | <1% | 582 | $263.23 | |
| 81025 | <1% | 520 | $243.18 | |
| 84550 | <1% | 1,265 | $224.01 | |
| 80050 | General health panel | <1% | 191 | $219.82 |
| 87205 | <1% | 94 | $212.44 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 955 | $199.99 |
| 87631 | <1% | 47 | $185.57 | |
| 97116 | <1% | 110 | $184.47 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 48 | $172.41 |
| G0008 | Administration of influenza virus vaccine | <1% | 389 | $168.15 |
| 73560 | <1% | 67 | $166.77 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 670 | $158.99 |
| 83880 | <1% | 816 | $154.92 | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 40 | $143.92 |
| 88108 | <1% | 15 | $139.29 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 2,131 | $133.08 |
| 88313 | <1% | 61 | $126.62 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 3,136 | $126.31 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 719 | $107.83 |
| 93325 | <1% | 33 | $101.14 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,511 | $100.23 |
| 85651 | <1% | 242 | $99.57 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,264 | $99.26 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 43 | $96.84 |
| 71250 | <1% | 66 | $91.24 | |
| 83021 | <1% | 150 | $85.73 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,462 | $77.18 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 43 | $71.44 |
| 86923 | <1% | 287 | $64.90 | |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | <1% | 190 | $58.64 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,706 | $58.24 |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 14 | $54.35 |
| 80197 | <1% | 808 | $50.01 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 986 | $43.67 |
| 85379 | <1% | 106 | $36.00 | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 28 | $29.43 |
| 91320 | <1% | 44 | $22.46 | |
| 87186 | <1% | 43 | $20.59 | |
| 85045 | <1% | 247 | $20.59 | |
| 90686 | <1% | 221 | $17.77 | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 46 | $17.69 |
| 86334 | <1% | 250 | $16.76 | |
| 80061 | Lipid panel | <1% | 59 | $10.30 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 2,973 | $9.49 |
| 83930 | <1% | 81 | $8.24 | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 868 | $5.96 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 1,650 | $1.97 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 86 | $0.90 |
| J1631 | Injection, haloperidol decanoate, per 50 mg | <1% | 181 | $0.02 |
| J2680 | Injection, fluphenazine decanoate, up to 25 mg | <1% | 97 | $0.02 |
| 90662 | 0% | 118 | $0.00 | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 178 | $0.00 |
| 96417 | 0% | 625 | $0.00 | |
| 84439 | 0% | 1,012 | $0.00 | |
| 84466 | 0% | 474 | $0.00 | |
| 83540 | 0% | 539 | $0.00 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 188 | $0.00 |
| 84165 | 0% | 389 | $0.00 | |
| 82570 | 0% | 110 | $0.00 | |
| J0688 | Injection, cefazolin sodium (hikma), not therapeutically equivalent to j0690, 500 mg | 0% | 13 | $0.00 |
| 96402 | 0% | 16 | $0.00 | |
| J3489 | Injection, zoledronic acid, 1 mg | 0% | 17 | $0.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 290 | $0.00 |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 0% | 102 | $0.00 |
| 93976 | 0% | 20 | $0.00 | |
| 82232 | 0% | 56 | $0.00 | |
| 82805 | 0% | 29 | $0.00 | |
| 87799 | 0% | 15 | $0.00 | |
| 97161 | 0% | 15 | $0.00 | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 0% | 14 | $0.00 |
| 83036 | Hemoglobin; glycosylated (A1C) | 0% | 300 | $0.00 |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 0% | 100 | $0.00 |
| 82607 | 0% | 73 | $0.00 | |
| 83883 | 0% | 208 | $0.00 | |
| 84153 | 0% | 174 | $0.00 | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 0% | 31 | $0.00 |
| 90480 | 0% | 44 | $0.00 | |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 12 | $0.00 |
| 86833 | 0% | 40 | $0.00 | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 0% | 79 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 30 | $0.00 |
| 82550 | 0% | 12 | $0.00 | |
| 73502 | 0% | 27 | $0.00 | |
| 90656 | 0% | 12 | $0.00 | |
| 87077 | 0% | 62 | $0.00 | |
| 87040 | 0% | 33 | $0.00 | |
| 76820 | 0% | 20 | $0.00 | |
| 72170 | 0% | 14 | $0.00 | |
| 97162 | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSPRINKEL, GEORGE (CFO)
| Provider | Location | Paid |
|---|---|---|
| University of Maryland Medical Center, LLC | Baltimore, MD | $18.03M |
| University of Maryland Medical Center, LLC | Baltimore, MD | $16.54M |
| University of Maryland Medical Center, LLC | Baltimore, MD | $10.19M |
| Maryland General Hospital, INC. | Baltimore, MD | $7.12M |
| Maryland General Hospital INC | Baltimore, MD | $3.33M |
| University of Maryland Midtown Health INC | Baltimore, MD | $3.15M |
| Maryland General Clinical Practice Group, INC. | Baltimore, MD | $1.38M |
| University of Maryland Medical Center, LLC | Baltimore, MD | $1.07M |
| University of Maryland Medical Center, LLC | Linthicum, MD | $804K |
| Maryland General Hospital, INC. | Baltimore, MD | $524K |
| Maryland General Clinical Practice Group, INC. | Baltimore, MD | $395K |
| University of Maryland Medical Center, LLC | Baltimore, MD | $210K |
| University of Maryland Medical Center, LLC | Baltimore, MD | $193K |
| University of Maryland Medical Center, LLC | Baltimore, MD | $59K |
| University of Maryland Medical Center, LLC | Baltimore, MD | $0.00 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.